Expression analysis of estrogen receptor α coregulators in breast carcinoma: Evidence that NCOR1 expression is predictive of the response to tamoxifen

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1259-1266

  Girault, Igor ^a   Lerebours, Florence ^a   Amarir, Samira ^c   Tozlu, Sengül ^a   Tubiana Hulin, Michèle ^a   Lidereau, Rosette ^a   Bièche, Ivan ^a,b  

^a CENTRE RENÉ HUGUENIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BB2; ESTROGEN RECEPTOR BETA; MESSENGER RNA; METASTASIS ASSOCIATED 1 LIKE 1 PROTEIN; MOLECULAR MARKER; NUCLEUS RECEPTOR COREPRESSOR 1; PROTEIN CCND1; PROTEIN NCOR1; REGULATOR PROTEIN; STEROID RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

A1B1 GENE; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; COACTIVATOR GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GCN5L2 GENE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; LYMPH NODE; MAJOR CLINICAL STUDY; MTA1L1 GENE; NCOR1 GENE; NUCLEOTIDE SEQUENCE; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; REGULATOR GENE; RELAPSE; REPRESSOR GENE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TIF2 GENE; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; DNA, COMPLEMENTARY; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAMOXIFEN; TIME FACTORS;

EID: 0037388540     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Klinge, C. M. Estrogen receptor interaction with co-activators and co-repressors. Steroids, 65: 227-251, 2000.
2. Mosselman, S., Polman, J., and Dijkema, R. ER β: identification and characterization of a novel human estrogen receptor. FEBS Lett., 392: 49-53, 1996.
3. Warnmark, A., Almlof, T., Leers, J., Gustafsson, J. A., and Treuter, E. Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERα and ERβ. J. Biol. Chem., 276: 23397-23404, 2001.
4. Lemon, B. D., and Freedman, L. P. Nuclear receptor cofactors as chromatin remodelers. Curr. Opin. Genet. Dev., 9: 499-504, 1999.
5. Alland, L., Muhle, R., Hou, H., Potes, J., Chin, L., Schreiber-Agus, N., and DePinho, R. A. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (Lond.), 387: 49-55, 1997.
6. McGuire, W. L., Clark, G. M., Dressler, L. G., and Owens, M. A. Role of steroid hormone receptors as prognostic factors in primary breast cancer. NCI Monogr., 1: 19-23, 1986.
7. Takimoto, G. S., Graham, J. D., Jackson, T. A., Tung, L., Powell, R. L., Horwitz, L. D., and Horwitz, K. B. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J. Steroid. Biochem. Mol. Biol., 69: 45-50, 1999.
8. Katzenellenbogen, B. S., Montano, M. M., Ekena, K., Herman, M. E., McInerney, E. M., and William, L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res. Treat., 44: 23-38, 1997.
9. Ellis, P. A., Saccani-Jotti, G., Clarke, R., Johnston, S. R., Anderson, E., Howell, A., A'Hern, R., Salter, J., Detre, S., Nicholson, R., Robertson, J., Smith, I. E., and Dowsett, M. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int. J. Cancer. 72: 608-613, 1997.
10. Perry, R., Kang, Y., and Greaves, B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and independent human breast cancer cells. Ann. Surg. Oncol., 2: 238-245, 1995.
11. Smith, C. L., Nawaz, Z., and O'Malley, B. W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol., 11: 657-666, 1997.
12. Voegel, J. J., Heine, M. J., Zechel, C., Chambon, P., and Gronemeyer, H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J., 15: 3667-3675, 1996.
13. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X. Y., Sauter, G., Kallioniemi, O. P., Trent, J. M., and Meltzer, P. S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (Wash. DC), 277: 965-968, 1997.
14. Wang, L., Mizzen, C., Ying, C., Candau, R., Barlev, N., Brownell, J., Allis, C. D., and Berger, S. L. Histone acetyltransferase activity is conserved between yeast and human GCN5 and is required for complementation of growth and transcriptional activation. Mol. Cell. Biol. 17: 519-527, 1997.
15. Horlein, A. J., Naar, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Soderstrom, M., and Glass, C. K. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (Lond.), 377: 397-404, 1995.
16. Futamura, M., Nishimori, H., Shiratsuchi, T., Saji, S., Nakamura, Y., and Tokino, T. Molecular cloning, mapping, and characterization of a novel human gene. MTA1-L1, showing homology to a metastasis-associated gene, MTA1. J. Hum. Genet., 44: 52-56, 1999.
17. Barnes, D. M., and Gillett, C. E. Cyclin D1 in breast cancer. Breast Cancer Res. Treat., 52: 1-15, 1998.
18. Yamauchi, H., Stearns, V., and Hayes, D. F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J. Clin. Oncol., 19: 2334-2356, 2001.
19. Planas-Silva, M. D., Shang, Y., Donaher, J. L., Brown, M., and Weinberg, R. A. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res., 61: 3858-3862, 2001.
20. Newman, S. P., Bates, N. P., Vernimmen, D., Parker, M. G., and Hurst, H. C. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene, 19: 490-497, 2000.
21. Bloom, H. J. G., and Richardson, W. W. Histological grading and prognosis in breast cancer. Br. J. Cancer, 11: 359-377, 1957.
22. Bieche, I., Onody, P., Laurendeau, I., Olivi, M., Vidaud, D., Lidereau, R., and Vidaud, M. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin. Chem., 45: 1148-1156, 1999.
23. Bieche, I., Parfait, B., Laurendeau, I., Girault, I., Vidaud, M., and Lidereau, R. Quantification of estrogen receptor α and β expression in sporadic breast cancer. Oncogene, 20: 8109-8115, 2001.
24. Bieche, I., Franc, B., Vidaud, D., Vidaud, M., and Lidereau, R. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid, 11: 147-152, 2001.
25. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
26. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
27. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc., 34: 187-220, 1972.
28. Bieche, I., Onody, P., Lerebours, F., Tozlu, S., Hacene, K., Andrieu, C., Vidaud, M., Tubiana-Hulin, M., Spyratos, F., and Lidereau, R. ERBB2 status and benefit from adjuvant tamoxifen in ERα-positive postmenopausal breast carcinoma. Cancer Lett., 174: 173-178, 2001.
29. Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., and Brown, M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell, 103: 843-852, 2000.
30. Bouras, T., Southey, M. C., and Venter, D. J. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res., 61: 903-907, 2001.
31. Kurebayashi, J., Otsuki, T., Kunisue, H., Tanaka, K., Yamamoto, S., and Sonoo, H. Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer. Clin. Cancer Res., 6: 512-518, 2000.
32. Cottone, E., Orso, F., Biglia, N., Sismondi, P., and De Bortoli, M. Role of coactivators and corepressors in steroid and nuclear receptor signaling: potential markers of tumor growth and drug sensitivity. Int. J. Biol. Markers, 16: 151-166, 2001.
33. Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T. M., Schiff, R., Del-Rio, A., Ricote, L., Ngo, M., Gemsch, S., Hilsenbeck, J., Osborne, S. G., Glass, C. K., Rosenfeld, C. K., and Rose, D. W. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA, 95: 2920-2925, 1998.
34. Yamamoto, Y., Wada, O., Suzawa, M., Yogiashi, Y., Yano, T., Kato, S., and Yanagisawa, J. The tamoxifen-responsive estrogen receptor α mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes. J. Biol. Chem., 276: 42684-42691, 2001.
35. Zhang, X., Jeyakumar, M., Petukhov, S., and Bagchi, M. K. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol. Endocrinol., 12: 513-524, 1998.
36. Jackson, T. A., Richer, J. K., Bain, D. L., Takimoto, G. S., Tung, L., and Horwitz, K. B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol., 11: 693-705, 1997.
37. Chan, C. M. W., Lykkesfeldt, A. E., Parker, M. G., and Dowsett, M. Expression of nuclear receptor interacting proteins TIF-1. SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer. Clin. Cancer Res., 5: 3460-3467, 1999.
38. Kurokawa, H., Lenferink, A. E., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., and Arteaga, C. L. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res., 60: 5887-5894, 2000.